How does diabetes accelerate Alzheimer disease pathology?

Diabetes and Alzheimer disease (AD)—two age-related diseases—are both increasing in prevalence, and numerous studies have demonstrated that patients with diabetes have an increased risk of developing AD compared with healthy individuals. The underlying biological mechanisms that link the development of diabetes with AD are not fully understood. Abnormal protein processing, abnormalities in insulin signaling, dysregulated glucose metabolism, oxidative stress, the formation of advanced glycation end products, and the activation of inflammatory pathways are features common to both diseases. Hypercholesterolemia is another factor that has received attention, owing to its potential association with diabetes and AD. This Review summarizes the mechanistic pathways that might link diabetes and AD. An understanding of this complex interaction is necessary for the development of novel drug therapies and lifestyle guidelines aimed at the treatment and/or prevention of these diseases.

[1]  J. Ávila,et al.  Analysis of microtubule-associated protein tau glycation in paired helical filaments. , 1994, The Journal of biological chemistry.

[2]  G. Biessels,et al.  Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment , 1998, Brain Research.

[3]  W. Markesbery,et al.  p38 Kinase Is Activated in the Alzheimer's Disease Brain , 1999, Journal of neurochemistry.

[4]  D L Alkon,et al.  Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. , 2005, Biochemical Society transactions.

[5]  J. L. François,et al.  Fibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer’s disease , 2001, Neuroscience.

[6]  A. Meinders,et al.  Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. , 2003, Atherosclerosis.

[7]  P. Kostyuk,et al.  Diabetes-induced changes in calcium homeostasis and the effects of calcium channel blockers in rat and mice nociceptive neurons , 2001, Diabetologia.

[8]  Geert Jan Biessels,et al.  The effects of type 1 diabetes on cognitive performance: a meta-analysis. , 2005, Diabetes care.

[9]  M. Kehry,et al.  CD40-mediated signaling in monocytic cells: up-regulation of tumor necrosis factor receptor-associated factor mRNAs and activation of mitogen-activated protein kinase signaling pathways. , 2001, International immunology.

[10]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[11]  Clay B. Holroyd,et al.  Potential roles of insulin and IGF-1 in Alzheimer ’ s disease , 2003 .

[12]  D. Bennett,et al.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.

[13]  B. Hemmings,et al.  Ten years of protein kinase B signalling: a hard Akt to follow. , 2001, Trends in biochemical sciences.

[14]  R. Studer,et al.  Effect of diabetes on hormone-stimulated and basal hepatocyte calcium metabolism. , 1989, Endocrinology.

[15]  D. Butterfield,et al.  Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: Implications for the role of nitration in the progression of Alzheimer's disease , 2007, Brain Research.

[16]  M. Kennedy,et al.  Hippocampal Neurons Predisposed to Neurofibrillary Tangle Formation Are Enriched in Type II Calcium/Calmodulin-Dependent Protein Kinase , 1990, Journal of neuropathology and experimental neurology.

[17]  J. Sowers,et al.  Diabetes mellitus: a disease of abnormal cellular calcium metabolism? , 1994, The American journal of medicine.

[18]  J. Wands,et al.  Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. , 2005, Journal of Alzheimer's disease : JAD.

[19]  Johanna Kuusisto,et al.  Association between features of the insulin resistance syndrome and alzheimer's disease independently of apolipoprotein e4 phenotype: cross sectional population based study , 1997, BMJ.

[20]  P. O'Brien,et al.  Risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997, American journal of epidemiology.

[21]  J. Kushner,et al.  Insulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation , 2003, The Journal of Neuroscience.

[22]  J. Luchsinger,et al.  Insulin Dysfunction Induces In Vivo Tau Hyperphosphorylation through Distinct Mechanisms , 2007, The Journal of Neuroscience.

[23]  A. Zmijewska,et al.  Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain In Vivo After Streptozotocin-Induced Insulin Deficiency , 2006, Diabetes.

[24]  V. Lee,et al.  Insulin and Insulin-like Growth Factor-1 Regulate Tau Phosphorylation in Cultured Human Neurons* , 1997, The Journal of Biological Chemistry.

[25]  S. Hoyer,et al.  Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis , 1998, Journal of Neural Transmission.

[26]  L. Murri,et al.  Causative and susceptibility genes for Alzheimer’s disease: a review , 2003, Brain Research Bulletin.

[27]  P. Moreira,et al.  Insulin protects against amyloid β-peptide toxicity in brain mitochondria of diabetic rats , 2005, Neurobiology of Disease.

[28]  V. Giguère,et al.  Phosphatases at the heart of FoxO metabolic control. , 2008, Cell metabolism.

[29]  A. Levey,et al.  Glycogen synthase kinase 3β and Alzheimer’s disease: pathophysiological and therapeutic significance , 2006, Cellular and Molecular Life Sciences CMLS.

[30]  Z. Khachaturian Calcium Hypothesis of Alzheimer's Disease and Brain Aging a , 1994, Annals of the New York Academy of Sciences.

[31]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[32]  S. Craft,et al.  Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. , 2004, European journal of pharmacology.

[33]  E. Masliah,et al.  Activation of the Amyloid Cascade in Apolipoprotein E4 Transgenic Mice Induces Lysosomal Activation and Neurodegeneration Resulting in Marked Cognitive Deficits , 2008, The Journal of Neuroscience.

[34]  Wei⁃qin Zhao,et al.  Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. , 2009, Biochimica et biophysica acta.

[35]  C. Cotman,et al.  Caspase-9 Activation and Caspase Cleavage of tau in the Alzheimer's Disease Brain , 2002, Neurobiology of Disease.

[36]  I. Deary,et al.  Is Type II Diabetes Associated With an Increased Risk of Cognitive Dysfunction?: A critical review of published studies , 1997, Diabetes Care.

[37]  S. Faraone,et al.  Diabetes and overweight associate with non‐APOE4 genotype in an alzheimer's disease population , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[38]  A. Zmijewska,et al.  Physiological and Pathological Changes in Glucose Regulate Brain Akt and Glycogen Synthase Kinase-3* , 2005, Journal of Biological Chemistry.

[39]  R. Dean,et al.  Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. , 1988, The Biochemical journal.

[40]  R. Schliebs,et al.  Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology , 2004, International Journal of Developmental Neuroscience.

[41]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[42]  A. Sima,et al.  Alzheimer-Like Changes in Rat Models of Spontaneous Diabetes , 2007, Diabetes.

[43]  K. Jellinger,et al.  Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease , 1998, Journal of Neural Transmission.

[44]  R. Powers,et al.  Transglutaminase activity is increased in Alzheimer's disease brain , 1997, Brain Research.

[45]  Eva L Feldman,et al.  Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. , 2009, Endocrinology.

[46]  Z. Makita,et al.  Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. , 1998, The American journal of pathology.

[47]  E. Masliah,et al.  Defective insulin signaling pathway and increased glycogen synthase kinase‐3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin , 2008, Journal of neuroscience research.

[48]  E. Feldman,et al.  Oxidative stress in the pathogenesis of diabetic neuropathy. , 2004, Endocrine reviews.

[49]  G. Johnson,et al.  The role of tau phosphorylation and cleavage in neuronal cell death. , 2007, Frontiers in bioscience : a journal and virtual library.

[50]  J. Saczynski,et al.  The Honolulu-Asia Aging Study , 2007 .

[51]  L. Launer,et al.  Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. , 2002, Diabetes.

[52]  Christian Hölscher,et al.  Common pathological processes in Alzheimer disease and type 2 diabetes: A review , 2007, Brain Research Reviews.

[53]  R. Kalaria,et al.  Nϵ-Carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease , 2004 .

[54]  T B Shea,et al.  Calcium‐Activated Neutral Proteinase (Calpain) System in Aging and Alzheimer's Disease a , 1994, Annals of the New York Academy of Sciences.

[55]  R. J. Williams,et al.  Elemental analysis of neurofibrillary tangles in Alzheimer's disease using proton-induced X-ray analysis. , 1992, Ciba Foundation symposium.

[56]  D. D. McKinley,et al.  Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer’s disease , 2001, Brain Research Bulletin.

[57]  S. Goodman,et al.  Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review , 2004, Neuroepidemiology.

[58]  T. Hilbum,et al.  From top to bottom , 1995 .

[59]  D. Selkoe Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[60]  C. Brayne,et al.  Vascular Risks and Incident Dementia: Results from a Cohort Study of the Very Old , 1998, Dementia and Geriatric Cognitive Disorders.

[61]  R. Jemmerson,et al.  Calcium‐induced Cytochrome c release from CNS mitochondria is associated with the permeability transition and rupture of the outer membrane , 2002, Journal of neurochemistry.

[62]  K. Nakashima,et al.  [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[63]  L. Plum,et al.  Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. , 2005, Diabetes.

[64]  George Perry,et al.  Oxidative stress in diabetes and Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[65]  D. Sparks,et al.  Cholesterol Accumulates in Senile Plaques of Alzheimer Disease Patients and in Transgenic APPsw Mice , 2001, Journal of neuropathology and experimental neurology.

[66]  G. Getz,et al.  Isoform-specific binding of apolipoprotein E to beta-amyloid. , 1994, The Journal of biological chemistry.

[67]  Wu Haibo A 6-year follow-up study of Cerec3 computer aided design and computer aided manufacture of all-ceramic crowns on implants , 2012 .

[68]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[69]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[70]  J. Götz,et al.  Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models , 2004, International Journal of Developmental Neuroscience.

[71]  M. Haan Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease , 2006, Nature Clinical Practice Neurology.

[72]  W. Noble,et al.  Kinase activities increase during the development of tauopathy in htau mice , 2007, Journal of neurochemistry.

[73]  M. Harris Hypercholesterolemia in Diabetes and Glucose Intolerance in the U.S. Population , 1991, Diabetes Care.

[74]  J. Götz,et al.  Experimental Diabetes Mellitus Exacerbates Tau Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2009, PloS one.

[75]  I. Björkhem,et al.  Oxysterols and Alzheimer's disease , 2006, Acta neurologica Scandinavica. Supplementum.

[76]  Ronald C Petersen,et al.  Increased risk of type 2 diabetes in Alzheimer disease. , 2004, Diabetes.

[77]  吉武毅人 Incidence and risk factors of vascular dementia and Alzheimer′s disease in a defined elderly Japanese population: The Hisayama Study(一般住民中の高齢者における脳血管性痴呆アルツハイマー病の発症率と危険因子の検討: 久山町研究) , 1997 .

[78]  R. Green,et al.  Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. , 2006, Archives of neurology.

[79]  J. Blass,et al.  The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. , 1991, Revue neurologique.

[80]  W. Noble,et al.  Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. , 2003, Brain research. Molecular brain research.

[81]  C. Masters,et al.  Copper-Dependent Inhibition of Human Cytochrome c Oxidase by a Dimeric Conformer of Amyloid-β1-42 , 2005, The Journal of Neuroscience.

[82]  S S Furuie,et al.  Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer’s disease: a combined MRI and SPECT study , 2002, Journal of neurology, neurosurgery, and psychiatry.

[83]  F. Schmidt Meta-Analysis , 2008 .

[84]  M. Zemel,et al.  Role of cellular calcium metabolism in abnormal glucose metabolism and diabetic hypertension. , 1989, The American journal of medicine.

[85]  C. Cotman,et al.  Apolipoprotein‐E Genotyping of Diabetic Dementia Patients: Is Diabetes Rare in Alzheimer's Disease? , 1996, Journal of the American Geriatrics Society.

[86]  D. Henze,et al.  The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. , 2006, Current topics in medicinal chemistry.

[87]  P. Moreira,et al.  Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes , 2007, Journal of the Neurological Sciences.

[88]  P. Barber,et al.  Diabetes, leukoencephalopathy and rage , 2006, Neurobiology of Disease.

[89]  S. Craft,et al.  Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice , 2006, Experimental Neurology.

[90]  W. Klein,et al.  Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ* , 2009, The Journal of Biological Chemistry.

[91]  R. Martins,et al.  Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease , 2006, Molecular Psychiatry.

[92]  A. Ott Risk of dementia: The Rotterdam Study , 1997 .

[93]  M. Reger,et al.  Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[94]  C. Morrison Leptin signaling in brain: A link between nutrition and cognition? , 2009, Biochimica et biophysica acta.

[95]  Ryuichi Morishita,et al.  Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes , 2010, Proceedings of the National Academy of Sciences.

[96]  P. Scheltens,et al.  Risk of dementia in diabetes mellitus: a systematic review , 2006, The Lancet Neurology.

[97]  Tony Wyss-Coray,et al.  Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice , 2004, The Journal of Neuroscience.

[98]  M. Beal,et al.  Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. , 2008, Trends in molecular medicine.

[99]  D. Alkon,et al.  Role of insulin and insulin receptor in learning and memory , 2001, Molecular and Cellular Endocrinology.

[100]  Jing He,et al.  Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. , 2002, Diabetes.

[101]  K. Rockwood,et al.  Diabetes mellitus and the Risk of Dementia, Alzheimer’s Disease and Vascular Cognitive Impairment in the Canadian Study of Health and Aging , 2002, Dementia and Geriatric Cognitive Disorders.

[102]  G. Johnson,et al.  Tau phosphorylation in neuronal cell function and dysfunction , 2004, Journal of Cell Science.

[103]  M. Mattson,et al.  Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. , 1999, Science.

[104]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[105]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[106]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[107]  P. Moreira,et al.  Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. , 2008, Free radical biology & medicine.

[108]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[109]  Claude Messier,et al.  The Relationship between Impaired Glucose Tolerance, Type 2 Diabetes, and Cognitive Function , 2004, Journal of clinical and experimental neuropsychology.

[110]  J. Heitner,et al.  Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects , 1997, Neurology.

[111]  A. Barden,et al.  Advanced Glycation End Products: A Review , 2013 .

[112]  A. Hofman,et al.  Insulin and Cognitive Function in an Elderly Population: The Rotterdam Study , 1997, Diabetes Care.

[113]  R. Berry,et al.  Tau polymerization: role of the amino terminus. , 2003, Biochemistry.

[114]  E. Masliah,et al.  Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice , 2010, Experimental Neurology.

[115]  Gopal Thinakaran,et al.  Amyloidogenic processing of β-amyloid precursor protein in intracellular compartments , 2006, Neurology.

[116]  N. Zilka,et al.  Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats , 2007, Brain Research.

[117]  G. Johnson,et al.  Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons , 2000, Neuroscience.

[118]  Prasanthi,et al.  Molecular Neurodegeneration Differential Effects of 24-hydroxycholesterol and 27-hydroxycholesterol on Β-amyloid Precursor Protein Levels and Processing in Human Neuroblastoma Sh-sy5y Cells , 2022 .

[119]  C. Bondy,et al.  Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. , 2005, Endocrinology.

[120]  C. Cotman,et al.  The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology , 2005, Journal of neuropathology and experimental neurology.

[121]  D. Praticò,et al.  Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.

[122]  M. Brownlee,et al.  Advanced protein glycosylation in diabetes and aging. , 1995, Annual review of medicine.

[123]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[124]  Raj Kalaria,et al.  N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease. , 2004, Free radical biology & medicine.

[125]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[126]  B. Hyman,et al.  Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. , 2000, The Journal of biological chemistry.

[127]  M. Robin,et al.  Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells , 2003, The Journal of cell biology.

[128]  B. Hyman,et al.  Modulation of β-Amyloid Precursor Protein Processing by the Low Density Lipoprotein Receptor-related Protein (LRP) , 2000, The Journal of Biological Chemistry.

[129]  Jongsoon Lee,et al.  The role of GSK3 in glucose homeostasis and the development of insulin resistance. , 2007, Diabetes research and clinical practice.

[130]  D. Jo,et al.  Proapoptotic Effects of Tau Cleavage Product Generated by Caspase-3 , 2001, Neurobiology of Disease.

[131]  H. Shimano,et al.  Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity. , 2008, Journal of lipid research.

[132]  E. Feldman,et al.  Oxidative injury and neuropathy in diabetes and impaired glucose tolerance , 2008, Neurobiology of Disease.

[133]  L S Honig,et al.  Aggregation of vascular risk factors and risk of incident Alzheimer disease , 2005, Neurology.

[134]  A. Korczyn The amyloid cascade hypothesis , 2008, Alzheimer's & Dementia.

[135]  G. Hart,et al.  O-GlcNAc modification in diabetes and Alzheimer's disease. , 2007, Molecular bioSystems.

[136]  J. Ordovás,et al.  Familial apolipoprotein E deficiency. , 1986, The Journal of clinical investigation.

[137]  Christina A. Wilson,et al.  GSK-3α regulates production of Alzheimer's disease amyloid-β peptides , 2003, Nature.

[138]  G. Biessels,et al.  Ageing and diabetes: implications for brain function. , 2002, European journal of pharmacology.

[139]  G. Paolisso,et al.  Oxidative Stress and Diabetic Vascular Complications , 1996, Diabetes Care.

[140]  K. Yaffe Metabolic syndrome and cognitive decline. , 2007, Current Alzheimer research.

[141]  S. Katsuki [Hisayama study]. , 1971, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[142]  Robert B. Petersen,et al.  Mitochondrial abnormalities in Alzheimer disease , 2000, Neurobiology of Aging.

[143]  I. Grundke‐Iqbal,et al.  Brain glucose transporters, O‐GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer’s disease , 2009, Journal of neurochemistry.

[144]  C. Schweiger [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[145]  Virginia M. Y. Lee,et al.  Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis , 2001, The Journal of Neuroscience.

[146]  C. Lines,et al.  Rofecoxib , 2004, Neurology.

[147]  Z. Makita,et al.  Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease , 2001, Brain Research.

[148]  Sunita Sharma,et al.  Hypercholesterolemia-induced Aβ accumulation in rabbit brain is associated with alteration in IGF-1 signaling , 2008, Neurobiology of Disease.

[149]  A. Ammit,et al.  Targeting p38 MAPK pathway for the treatment of Alzheimer's disease , 2010, Neuropharmacology.

[150]  D. Selkoe,et al.  Calcium ionophore increases amyloid beta peptide production by cultured cells. , 1994, Biochemistry.

[151]  T. Pozzan,et al.  Mitochondria as biosensors of calcium microdomains. , 1999, Cell calcium.

[152]  W. Noble,et al.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[153]  Rong Wang,et al.  Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model , 2000, Neurobiology of Disease.

[154]  T. Ohm,et al.  Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons , 2001, Acta Neuropathologica.

[155]  D. Small,et al.  Alzheimer's disease and Aβ toxicity: from top to bottom , 2001, Nature Reviews Neuroscience.